Loading...

Vaccinex

Nasdaq:VCNX
Snowflake Description

Adequate balance sheet with limited growth.

The Snowflake is generated from 30 checks in 5 different areas, read more below.
VCNX
Nasdaq
$79M
Market Cap
  1. Home
  2. US
  3. Pharmaceuticals & Biotech
Company description

Vaccinex, Inc., a clinical-stage biotechnology company, discovers and develops bio therapeutics to treat serious diseases and conditions with unmet medical needs, including cancer, neurodegenerative diseases, and autoimmune disorders. The last earnings update was 5 days ago. More info.


Add to Portfolio Compare Print
  • Vaccinex has significant price volatility in the past 3 months.
VCNX Share Price and Events
7 Day Returns
-11.1%
NasdaqGM:VCNX
-1.6%
US Biotechs
-0.7%
US Market
1 Year Returns
-
NasdaqGM:VCNX
-5.5%
US Biotechs
3%
US Market
VCNX Shareholder Return
  7 Day 30 Day 90 Day 1 Year 3 Year 5 Year
Vaccinex (VCNX) -11.1% 34.2% 50.6% - - -
US Biotechs -1.6% -5.5% -6.5% -5.5% 9.7% 12%
US Market -0.7% -2% 2.4% 3% 39.2% 42%
1 Year Return vs Industry and Market
  • No trading data on VCNX.
  • No trading data on VCNX.
Price Volatility
Industry
5yr Volatility vs Market
Related Companies

Value

 Is Vaccinex undervalued based on future cash flows and its price relative to the stock market?

Value is all about what a company is worth versus what price it is available for. If you went into a grocery store and all the bananas were on sale at half price, they could be considered undervalued.

In this section, we usually try to help investors determine whether Vaccinex is trading at an attractive price based on the cash flow it is expected to produce in the future. But as Vaccinex has not provided consistent financial data, and the stock also has no analyst forecast or coverage, its intrinsic value cannot be reliably calculated by extrapolating past data or using analyst consensus cash flow predictions.

This is quite a rare situation as 89% of companies covered by Simply Wall St do have a valuation analysis. You can see them here.

Show me the analysis anyway

INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
  • It is not possible to calculate the future cash flow value for Vaccinex. This is due to cash flow or dividend data being unavailable. The share price is $6.9.
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing when they are out of season, or how much your home is worth.

The amount the stock market is willing to pay for Vaccinex's earnings, growth and assets is considered below, and whether this is a fair price.
Price based on past earnings
Are Vaccinex's earnings available for a low price, and how does this compare to other companies in the same industry?
Raw Data
NasdaqGM:VCNX PE (Price to Earnings) Ratio Data Sources
Data Point Source Value
Earnings Per Share * Company Filings (2019-03-31) in USD $-3.93
NasdaqGM:VCNX Share Price ** NasdaqGM (2019-05-17) in USD $6.9
United States of America Biotechs Industry PE Ratio Median Figure of 34 Publicly-Listed Biotechs Companies 19.48x
United States of America Market PE Ratio Median Figure of 3,088 Publicly-Listed Companies 17.89x

* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.

** Primary Listing of Vaccinex.

NasdaqGM:VCNX PE (Price to Earnings) Ratio Calculation
Calculation Outcome
PE Ratio

= NasdaqGM:VCNX Share Price ÷ EPS (both in USD)

= 6.9 ÷ -3.93

-1.76x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Vaccinex is loss making, we can't compare its value to the US Biotechs industry average.
  • Vaccinex is loss making, we can't compare the value of its earnings to the United States of America market.
Price based on expected Growth
Does Vaccinex's expected growth come at a high price?
Raw Data
NasdaqGM:VCNX PEG (Price to Earnings to Growth) Ratio Data Sources
Data Point Source Value
PE Ratio See PE Ratio Section -1.76x
Net Income Annual Growth Rate See Future Growth Section.
Line of Best Fit* through Consensus Estimate Earnings of 3 Analysts
-1%per year
United States of America Biotechs Industry PEG Ratio Median Figure of 27 Publicly-Listed Biotechs Companies 1.32x
United States of America Market PEG Ratio Median Figure of 2,117 Publicly-Listed Companies 1.56x

*Line of best fit is calculated by linear regression .

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to calculate PEG ratio for Vaccinex, we can't assess if its growth is good value.
Price based on value of assets
What value do investors place on Vaccinex's assets?
Raw Data
NasdaqGM:VCNX PB (Price to Book) Ratio Data Sources
Data Point Source Value
Book Value per Share Company Filings (2019-03-31) in USD $-1.54
NasdaqGM:VCNX Share Price * NasdaqGM (2019-05-17) in USD $6.9
United States of America Biotechs Industry PB Ratio Median Figure of 416 Publicly-Listed Biotechs Companies 3.21x
United States of America Market PB Ratio Median Figure of 5,195 Publicly-Listed Companies 1.83x
NasdaqGM:VCNX PB (Price to Book) Ratio Calculation
Calculation Outcome
PB Ratio

= NasdaqGM:VCNX Share Price ÷ Book Value per Share (both in USD)

= 6.9 ÷ -1.54

-4.49x

* Primary Listing of Vaccinex.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Vaccinex has negative assets, we can't compare the value of its assets to the US Biotechs industry average.

Next steps:

  1. Examine Vaccinex's financial health to determine how well-positioned it is against times of financial stress by looking at its level of debt over time and how much cash it has left.
  2. When valuing a company like this, investors focus more on how they perceive the size of the opportunity, the company's ability to deliver and scale, and the strength of the team. While we are not analysing this type of data at the moment, if you don’t know where to start, we recommend reading through Vaccinex's regulatory filings and announcements.
  3. Show me more potentially undervalued companies in the Biotechs industry
  4. Use fundamentals to screen for another stock to analyse from our database of over 75,000 companies worldwide
X
Value checks
We assess Vaccinex's value by looking at:
  1. Is the discounted cash flow value less than 20%, or 40% of the share price? (2 checks) ( Click here or on bar chart for details of DCF calculation. )
  2. Is the PE ratio less than the market average, and/ or less than the Biotechs industry average (and greater than 0)? (2 checks)
  3. Is the PEG ratio within a reasonable range (0 to 1)? (1 check)
  4. Is the PB ratio less than the Biotechs industry average (and greater than 0)? (1 check)
  5. Vaccinex has a total score of 0/6, see the detailed checks below.

    Note: We use GAAP Earnings per Share in all our calculations including PE and PEG Ratio.

    Full details on the Value part of the Simply Wall St company analysis model.

Future Performance

 How is Vaccinex expected to perform in the next 1 to 3 years based on estimates from 3 analysts?

The future performance of a company is measured in the same way as past performance, by looking at estimated growth and how much profit it is expected to make.

Future estimates come from professional analysts. Just like forecasting the weather, they don’t always get it right!
Annual Growth Rate
-1%
Expected annual growth in earnings.
Earnings growth vs Low Risk Savings
Is Vaccinex expected to grow at an attractive rate?
  • Unable to compare Vaccinex's earnings growth to the low risk savings rate as it is expected to be loss making during the next 1-3 years.
Growth vs Market Checks
  • Unable to compare Vaccinex's earnings growth to the United States of America market average as it is expected to be loss making during the next 1-3 years.
  • Vaccinex's revenue growth is expected to exceed the United States of America market average.
Annual Growth Rates Comparison
Raw Data
NasdaqGM:VCNX Future Growth Rates Data Sources
Data Point Source Value (per year)
NasdaqGM:VCNX Future Earnings Growth Rate Line of Best Fit* through Consensus Estimate Earnings of 3 Analysts -1%
NasdaqGM:VCNX Future Revenue Growth Rate Line of Best Fit* through Consensus Estimate Revenue of 3 Analysts 68%
United States of America Biotechs Industry Earnings Growth Rate Market Cap Weighted Average 22.6%
United States of America Biotechs Industry Revenue Growth Rate Market Cap Weighted Average 17.5%
United States of America Market Earnings Growth Rate Market Cap Weighted Average 13.9%
United States of America Market Revenue Growth Rate Market Cap Weighted Average 7.3%

*Line of best fit is calculated by linear regression .

Industry and Market average data is calculated daily.

Learn more about our growth rate calculations in Simply Wall St’s analysis model.

Analysts growth expectations
Raw Data
NasdaqGM:VCNX Analysts Growth Expectations Data Sources
Data Point Source Value
Past Financials Company Filings (1 month ago) See Below
Future Estimates Average of up to 3 Analyst Estimates (S&P Global) See Below
All numbers in USD Millions and using Trailing twelve months (TTM) annual period rather than quarterly.
NasdaqGM:VCNX Future Estimates Data
Date (Data in USD Millions) Revenue Cash Flow Net Income * Avg. No. Analysts
2023-12-31 286 1
2022-12-31 70 -28 2
2021-12-31 14 -45 2
2020-12-31 3 -41 3
2019-12-31 0 -36 3
NasdaqGM:VCNX Past Financials Data
Date (Data in USD Millions) Revenue Cash Flow Net Income *
2019-03-31 1 -29 -31
2018-12-31 1 -25 -30
2018-09-30 1 -24 -24
2018-06-30 0 -21 -24
2018-03-31 0 -22 -24
2017-12-31 0 -21 -22
2016-12-31 0 -20 -26

*GAAP earnings excluding extraordinary items.

Super high growth metrics
High Growth Checks
  • Vaccinex is not considered high growth as it is expected to be loss making for the next 1-3 years.
  • Vaccinex's revenue is expected to grow significantly at over 20% yearly.
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can be gauged below. We look back 3 years and see if they were any good at predicting what actually occurred. We also show the highest and lowest estimates looking forward to see if there is a wide range.
Raw Data
NasdaqGM:VCNX Past and Future Earnings per Share
Data Point Source Value
Past Financials Company Filings (1 month ago) See Below
Future Estimates Average of up to 3 Analyst Estimates (S&P Global) See Below

All data from Vaccinex Company Filings, last reported 1 month ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

NasdaqGM:VCNX Future Estimates Data
Date (Data in USD Millions) EPS * EPS High Estimate EPS Low Estimate Avg. No. Analysts
2023-12-31
2022-12-31 -1.09 -1.09 -1.09 1.00
2021-12-31 -3.14 -1.88 -4.40 2.00
2020-12-31 -2.70 -1.73 -4.08 3.00
2019-12-31 -2.51 -2.21 -2.85 3.00
NasdaqGM:VCNX Past Financials Data
Date (Data in USD Millions) EPS *
2019-03-31 -3.93
2018-12-31 -5.65
2018-09-30 -9.36
2018-06-30 -21.64
2018-03-31 -21.84
2017-12-31 -19.90
2016-12-31 -25.27

*GAAP earnings excluding extraordinary items.

Performance in 3 years
In the same way as past performance we look at the future estimated return (profit) compared to the available funds. We do this looking forward 3 years.
  • Unable to establish if Vaccinex will efficiently use shareholders’ funds in the future without estimates of Return on Equity.
X
Future performance checks
We assess Vaccinex's future performance by looking at:
  1. Is the annual earnings growth rate expected to beat the low risk savings rate, plus a premium to keep pace with inflation?
  2. Is the annual earnings growth rate expected to beat the average growth rate in earnings of the United States of America market? (1 check)
  3. Is the annual revenue growth rate expected to beat the average growth rate in revenue of the United States of America market? (1 check)
  4. Is the annual earnings growth rate expected to be above 20%? (1 check)
  5. Is the annual revenue growth rate expected to be above 20%? (1 check)
  6. Is the Return on Equity in 3 years expected to be over 20%? (1 check)
Some of the above checks will fail if the company is expected to be loss making in the relevant year.
Vaccinex has a total score of 2/6, see the detailed checks below.

Note 1: We use GAAP Net Income Excluding Exceptional Items for our Earnings in all our calculations.

Full details on the Future part of the Simply Wall St company analysis model.

Past Performance

  How has Vaccinex performed over the past 5 years?

The past performance of a company can be measured by how much growth it has experienced and how much profit it makes relative to the funds and assets it has available.
Past earnings growth
Below we compare Vaccinex's growth in the last year to its industry (Biotechs).
Past Earnings growth analysis
We also check if the company has grown in the past 5 years, and whether it has maintained that growth in the year.
  • Vaccinex does not make a profit and there is insufficient past data to establish if their 5 year on year earnings growth rate was positive.
  • Unable to compare Vaccinex's 1-year earnings growth to the 5-year average as it is not currently profitable.
  • Unable to compare Vaccinex's 1-year growth to the US Biotechs industry average as it is not currently profitable.
Earnings and Revenue History
Vaccinex's revenue and profit over the past 5 years is shown below, any years where they have experienced a loss will show up in red.
Raw Data

All data from Vaccinex Company Filings, last reported 1 month ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

NasdaqGM:VCNX Past Revenue, Cash Flow and Net Income Data
Date (Data in USD Millions) Revenue Net Income * G+A Expenses R&D Expenses
2019-03-31 0.61 -30.72 5.05 25.31
2018-12-31 0.72 -29.52 4.62 22.35
2018-09-30 0.62 -24.47 4.34 20.31
2018-06-30 0.42 -24.22 4.29 19.29
2018-03-31 0.30 -24.08 4.63 17.17
2017-12-31 0.09 -21.93 4.48 16.55
2016-12-31 0.32 -26.23 4.43 16.03

*GAAP earnings excluding extraordinary items.

Performance last year
We want to ensure a company is making the most of what it has available. This is done by comparing the return (profit) to a company's available funds, assets and capital.
  • It is difficult to establish if Vaccinex has efficiently used shareholders’ funds last year (Return on Equity greater than 20%) as it is loss-making.
  • It is difficult to establish if Vaccinex has efficiently used its assets last year compared to the US Biotechs industry average (Return on Assets) as it is loss-making.
  • It is difficult to establish if Vaccinex improved its use of capital last year versus 3 years ago (Return on Capital Employed) as it is currently loss-making.
X
Past performance checks
We assess Vaccinex's performance over the past 5 years by checking for:
  1. Has earnings increased in past 5 years? (1 check)
  2. Has the earnings growth in the last year exceeded that of the Biotechs industry? (1 check)
  3. Is the recent earnings growth over the last year higher than the average annual growth over the past 5 years? (1 check)
  4. Is the Return on Equity (ROE) higher than 20%? (1 check)
  5. Is the Return on Assets (ROA) above industry average? (1 check)
  6. Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent earnings report. Some checks require at least 3 or 5 years worth of data.
Vaccinex has a total score of 0/6, see the detailed checks below.

Note: We use GAAP Net Income excluding extraordinary items in all our calculations.

Full details on the Past part of the Simply Wall St company analysis model.

Health

 How is Vaccinex's financial health and their level of debt?

A company's financial position is much like your own financial position, it includes everything you own (assets) and owe (liabilities).

The boxes below represent the relative size of what makes up Vaccinex's finances.

The net worth of a company is the difference between its assets and liabilities.
Net Worth
  • Vaccinex is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
  • Vaccinex has no long term commitments.
Balance sheet
This treemap shows a more detailed breakdown of Vaccinex's finances. If any of them are yellow this indicates they may be out of proportion and red means they relate to one of the checks below.
Assets
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
  • Low level of unsold assets.
  • Vaccinex has no debt, it does not need to be covered by short term assets.
Historical Debt
Nearly all companies have debt. Debt in itself isn’t bad, however if the debt is too high, or the company can’t afford to pay the interest on its debts this may have impacts in the future.

The graphic below shows equity (available funds) and debt, we ideally want to see the red area (debt) decreasing.

If there is any debt we look at the companies capability to repay it, and whether the level has increased over the past 5 years.
Raw Data

All data from Vaccinex Company Filings, last reported 1 month ago.

NasdaqGM:VCNX Past Debt and Equity Data
Date (Data in USD Millions) Total Equity Total Debt Cash & Short Term Investments
2019-03-31 6.34 0.00 11.29
2018-12-31 15.34 0.00 19.72
2018-09-30 23.75 0.00 27.38
2018-06-30 -4.15 1.28 1.30
2018-03-31 -1.60 1.23 2.92
2017-12-31 -1.77 2.81 4.18
2016-12-31 -3.33 1.04 1.66
  • Vaccinex has no debt.
  • Vaccinex currently has no debt however we can't compare to 5 years ago as we have no data for that period.
CASH RUNWAY ANALYSIS

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

  • Vaccinex has less than a year of cash runway based on current free cash flow.
  • Vaccinex has less than a year of cash runway if free cash flow continues to grow at historical rates of 13.9% each year.
X
Financial health checks
We assess Vaccinex's financial health by checking for:
  1. Are short term assets greater than short term liabilities? (1 check)
  2. Are short term assets greater than long term liabilities? (1 check)
  3. Has the debt to equity ratio increased in the past 5 years? (1 check)
  4. Is the debt to equity ratio over 40%? (1 check)
  5. Is the debt covered by operating cash flow? (1 check)
  6. Are earnings greater than 5x the interest on debt (if company pays interest at all)? (1 check)
  7. Vaccinex has a total score of 4/6, see the detailed checks below.
For companies that are loss making and have been so on average in the past we replace the last 2 checks with:
  1. Does cash and short term investments cover stable operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
  2. Does cash and short term investments cover growing operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)


Full details on the Health part of the Simply Wall St company analysis model.

Dividends

 What is Vaccinex's current dividend yield, its reliability and sustainability?

Dividends are regular cash payments to you from the company, similar to a bank paying you interest on a savings account.
Annual Dividend Income
Dividend payments
0%
Current annual income from Vaccinex dividends.
If you bought $2,000 of Vaccinex shares you are expected to receive $0 in your first year as a dividend.
Dividend Amount
Here we look how much dividend is being paid, if any. Is it above what you can get in a savings account? It is up there with the best dividend paying companies?
  • Unable to evaluate Vaccinex's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
  • Unable to evaluate Vaccinex's dividend against the top 25% market benchmark as the company has not reported any payouts.
Annualized Historical and Future Dividends
It is important to see if the dividend for a company is stable, and not wildly increasing/decreasing each year. This graph shows you the historical rate to count toward your assessment of the stock.

We also check to see if the dividend has increased in the past 10 years.
Raw Data
NasdaqGM:VCNX Annualized Past and Future Dividends
Data Point Source Value
Past Annualized Dividend Yield S&P Global Market Data See Below
Past Dividends per Share Company Filings/ Annualized Dividend Payments See Below
Future Dividends per Share Estimates Average of up to 3 Analyst Estimates (S&P Global) See Below
Global Biotechs Industry Average Dividend Yield Market Cap Weighted Average of 19 Stocks 2.4%
United States of America Market Average Dividend Yield Market Cap Weighted Average of 2000 Stocks 2.5%
United States of America Minimum Threshold Dividend Yield 10th Percentile 0.8%
United States of America Bottom 25% Dividend Yield 25th Percentile 1.4%
United States of America Top 25% Dividend Yield 75th Percentile 3.7%

Industry and Market average data is calculated daily.

Note all dividend per share amounts are annualized and not quarterly or other period.

NasdaqGM:VCNX Future Dividends Estimate Data
Date (Data in $) Dividend per Share (annual) Avg. No. Analysts
2023-12-31
2022-12-31
2021-12-31
2020-12-31
2019-12-31

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to perform a dividend volatility check as Vaccinex has not reported any payouts.
  • Unable to verify if Vaccinex's dividend has been increasing as the company has not reported any payouts.
Current Payout to shareholders
What portion of Vaccinex's earnings are paid to the shareholders as a dividend.
  • Unable to calculate sustainability of dividends as Vaccinex has not reported any payouts.
Future Payout to shareholders
  • Insufficient estimate data to determine if a dividend will be paid in 3 years and that it will be sustainable.
X
Income/ dividend checks
We assess Vaccinex's dividend by checking for:
  1. Firstly is the company paying a notable dividend (greater than 0.8%) - if not then the rest of the checks are ignored.
  2. Is current dividend yield above the bottom 25% of dividend payers? (1 check)
  3. Is current dividend yield above the top 25% of dividend payers? (1 check)
  4. Have they paid a dividend for 10 years, and during this period has the dividend been volatile (drop of more than 25%)? (1 check)
  5. If they have paid a dividend for 10 years has it increased in this time? (1 check)
  6. How sustainable is the dividend, can Vaccinex afford to pay it from its earnings today and in 3 years (Payout ratio less than 90%)? (2 checks)
  7. Vaccinex has a total score of 0/6, see the detailed checks below.


Full details on the Dividends part of the Simply Wall St company analysis model.

Management

 What is the CEO of Vaccinex's salary, the management and board of directors tenure and is there insider trading?

Management is one of the most important areas of a company. We look at unreasonable CEO compensation, how long the team and board of directors have been around for and insider trading.
CEO
Maurice Zauderer
COMPENSATION $336,768
AGE 72
TENURE AS CEO 18.1 years
CEO Bio

Dr. Maurice Zauderer, Ph.D. Co-Founded Vaccinex, Inc. in April 2001 and also serves as its President and Chief Executive Officer since April 2001. Dr. Zauderer serves as Director of Vaccinex Inc. since April 2001. Prior to founding Vaccinex, Dr. Zauderer served as an Associate Professor of the University of Rochester and has also held faculty appointments at Columbia University. During his academic career, he held the position of visiting scientist at the Laboratory of Cell Biology (Rome, Italy), the Ontario Cancer Institute (Toronto, Canada), and at the National Cancer Institute (Bethesda, Maryland). He is also a member of the board of directors of the New York Biotechnology Association (NYBA). Dr. Zauderer holds a Ph.D. in cell biology from the Massachusetts Institute of Technology.

CEO Compensation
  • Maurice's compensation has been consistent with company performance over the past year.
  • Maurice's remuneration is about average for companies of similar size in United States of America.
Management Team Tenure

Average tenure and age of the Vaccinex management team in years:

10.4
Average Tenure
60
Average Age
  • The average tenure for the Vaccinex management team is over 5 years, this suggests they are a seasoned and experienced team.
Management Team

Maurice Zauderer

TITLE
Co-Founder
COMPENSATION
$337K
AGE
72
TENURE
18.1 yrs

Raymond Watkins

TITLE
Senior VP & COO
COMPENSATION
$235K
AGE
60
TENURE
13.3 yrs

Ernest Smith

TITLE
Senior VP of Research & Chief Scientific Officer
COMPENSATION
$235K
AGE
46
TENURE
10.4 yrs

Deepak Sahasrabudhe

TITLE
Co-Founder

Scott Royer

TITLE
Chief Financial Officer
AGE
44
TENURE
1.3 yrs

John Leonard

TITLE
Senior Vice President of Development
AGE
71
TENURE
10.3 yrs
Board of Directors Tenure

Average tenure and age of the Vaccinex board of directors in years:

16.2
Average Tenure
67
Average Age
  • The average tenure for the Vaccinex board of directors is over 10 years, this suggests they are a seasoned and experienced board.
Board of Directors

Albert Friedberg

TITLE
Chairman of the Board
AGE
71
TENURE
18.1 yrs

Maurice Zauderer

TITLE
Co-Founder
COMPENSATION
$337K
AGE
72
TENURE
18.1 yrs

Deepak Sahasrabudhe

TITLE
Co-Founder

Gerald Van Strydonck

TITLE
Director
COMPENSATION
$20K
AGE
73
TENURE
16.2 yrs

Jeff Goater

TITLE
Director
COMPENSATION
$17K
AGE
43
TENURE
6 yrs

Barbara Yanni

TITLE
Director
COMPENSATION
$18K
AGE
63
TENURE
4.3 yrs

Jacob Frieberg

TITLE
Lead Director
COMPENSATION
$14K
AGE
61

Alan Crane

TITLE
Director
COMPENSATION
$14K
AGE
55
TENURE
16.2 yrs

Bala Manian

TITLE
Director
COMPENSATION
$14K
AGE
73
TENURE
14.4 yrs

Max Vasquez

TITLE
Member of Scientific & Clinical Advisory Board
Who owns this company?
Recent Insider Trading
  • No 3 month insider trading information.
Recent Insider Transactions
Announced Type Name Entity Role Start End Shares Max Price ($) Value ($)
08. Feb 19 Buy Scott Royer Individual 06. Feb 19 07. Feb 19 2,000 $5.05 $9,968
17. Jan 19 Buy Scott Royer Individual 15. Jan 19 15. Jan 19 1,688 $4.31 $7,275
31. Dec 18 Buy Scott Royer Individual 27. Dec 18 27. Dec 18 311 $4.15 $1,291
15. Aug 18 Buy Friedberg Mercantile Group Ltd., Asset Management Arm Company 13. Aug 18 13. Aug 18 583,333 $12.00 $6,999,996
15. Aug 18 Buy FCMI Parent Co. Company 13. Aug 18 13. Aug 18 1,875,000 $12.00 $22,500,000
X
Management checks
We assess Vaccinex's management by checking for:
  1. Is the CEO's compensation unreasonable compared to market cap? (1 check)
  2. Has the CEO's compensation increased more than 20% whilst the EPS is down more then 20%? (1 check)
  3. Is the average tenure of the management team less than 2 years? (1 check)
  4. Is the average tenure of the board of directors team less than 3 years? (1 check)
  5. Vaccinex has a total score of 0/6, this is not included on the snowflake, see the detailed checks below.


Note: We use the top 6 management executives and board members in our calculations.

Note 2: Insider trading include any internal stakeholders and these transactions .

Full details on the Management part of the Simply Wall St company analysis model.

News

Simply Wall St News

Do Directors Own Vaccinex, Inc. (NASDAQ:VCNX) Shares?

Generally speaking, as a company grows, institutions will increase their ownership. … Conversely, insiders often decrease their ownership over time. … Vaccinex is not a large company by global standards.

Simply Wall St -

Is Vaccinex Inc (NASDAQ:VCNX) A Financially Sound Company?

The direct benefit for Vaccinex Inc (NASDAQ:VCNX), which sports a zero-debt capital structure, to include debt in its capital structure is the reduced cost of capital. … However, the trade-off is VCNX will have to adhere to stricter debt covenants and have less financial flexibility. … Is VCNX right in choosing financial flexibility over lower cost of capital.

Simply Wall St -

Company Info

Description

Vaccinex, Inc., a clinical-stage biotechnology company, discovers and develops bio therapeutics to treat serious diseases and conditions with unmet medical needs, including cancer, neurodegenerative diseases, and autoimmune disorders. Its lead product candidate is pepinemab that is in clinical development stage for the treatment of non-small cell lung cancer (NSCLC), osteosarcoma, melanoma, and Huntington’s disease. The company is also developing VX5, a human antibody to CXCL13 that is in preclinical development for the treatment of MS and potentially for other autoimmune disorders; VX25, a bi-specific natural killer T (NKT) cell stimulator, for the therapeutic application of NKT cell stimulation for cancer immunotherapy; BVX20, an investigational and humanized monoclonal antibody for the treatment of for multiple sclerosis. It has a clinical trial collaboration and supply agreement with Merck KGaA to test pepinemab in combination with avelumab checkpoint inhibitor in NSCLC patients. Vaccinex, Inc. was founded in 2001 and is headquartered in Rochester, New York.

Details
Name: Vaccinex, Inc.
VCNX
Exchange: NasdaqGM
Founded: 2001
$79,182,668
11,475,749
Website: http://www.vaccinex.com
Address: Vaccinex, Inc.
1895 Mount Hope Avenue,
Rochester,
New York, 14620,
United States
Listings
Exchange Symbol Ticker Symbol Security Exchange Country Currency Listed on
NasdaqGM VCNX Common Stock Nasdaq Global Market US USD 09. Aug 2018
Number of employees
Current staff
Staff numbers
44
Vaccinex employees.
Industry
Biotechnology
Pharmaceuticals & Biotech
Company Analysis and Financial Data Status
Area Date (UTC time)
Company Analysis updated: 2019/05/20 03:10
End of day share price update: 2019/05/17 00:00
Last estimates confirmation: 2019/05/16
Last earnings filing: 2019/05/15
Last earnings reported: 2019/03/31
Last annual earnings reported: 2018/12/31


All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.